PAHC
Phibro Animal HealthDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The quarter showed solid underlying animal-health demand, with strength in MFAs, nutritional specialties, and vaccines, and management raised full-year guidance while improving liquidity, which supports the idea that the core business is still compounding [#SEC-8K-2026-05-06].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
Brazil's antimicrobial regulatory transition may reduce or reshape certain product sales and create temporary margin pressure [#SEC-8K-2026-05-06].
Momentum
10
Value
57
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $39.00 · Bull $49.00 · Bear $28.00
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $45.60
Why
Momentum10 · Δ7d +2.8
Value57 · Δ7d -0.1
Sentiment64 · Δ7d -9.3
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
10
26% active weight
Current posture
7d trendImproving
Δ7d
+2.8
Δ21d
+4.4
Value
57
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.4
Sentiment
64
34% active weight
Current posture
7d trendSoftening
Δ7d
-9.3
Δ21d
-7.8
Why this grade
Composite grade D. Momentum 9.6 / Value 56.6 / Sentiment 64.2
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$1.34B
Beta
0.79
Shares Out
40.56M
P/E (TTM)
23.1
P/S (TTM)
1.11
P/FCF (TTM)
104.84
Rev YoY
+10.3%
EPS YoY
+14.1%
Gross Margin
+32.3%
Op Margin
+10.3%
Net Debt
$684.51M
Current Ratio
3.17
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology